{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:18:43Z","timestamp":1787761123814,"version":"build-2784847793"},"reference-count":48,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["PY202335"],"award-info":[{"award-number":["PY202335"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2415200"],"award-info":[{"award-number":["2023YFC2415200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ejso.2025.109752","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T23:32:19Z","timestamp":1741303939000},"page":"109752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Identifying potential beneficiaries of neoadjuvant therapy in borrmann type III and IV gastric cancer: A treatment heterogeneity analysis using causal survival forests"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0020-333X","authenticated-orcid":false,"given":"Jiyao","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinkui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangxi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongning","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rulin","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhemin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouqiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2096-6526","authenticated-orcid":false,"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiafu","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejso.2025.109752_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.ejso.2025.109752_bib2","first-page":"115","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.ejso.2025.109752_bib3","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s10120-024-01546-x","article-title":"Oncological similarities between large type 3 and type 4 tumors in patients with resectable gastric cancer: a propensity score-matched analysis of a multi-institutional dataset","volume":"27","author":"Nakanishi","year":"2024","journal-title":"Gastric Cancer"},{"issue":"2","key":"10.1016\/j.ejso.2025.109752_bib4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, version 2.2022, NCCN clinical practice guidelines in Oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"issue":"1","key":"10.1016\/j.ejso.2025.109752_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejso.2025.109752_bib6","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"Zhang","year":"2021","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.ejso.2025.109752_bib7","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.20.02914","article-title":"PRODIGY: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer","volume":"39","author":"Kang","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2025.109752_bib8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s10120-020-01136-7","article-title":"Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial","volume":"24","author":"Iwasaki","year":"2021","journal-title":"Gastric Cancer"},{"issue":"4","key":"10.1016\/j.ejso.2025.109752_bib9","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.21873\/anticanres.16303","article-title":"Gastric linitis plastica: clinical characteristics and outcomes from the national cancer Database","volume":"43","author":"Ayub","year":"2023","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.ejso.2025.109752_bib10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jrsssb\/qkac001","article-title":"Estimating heterogeneous treatment effects with right-censored data via causal survival forests","volume":"85","author":"Cui","year":"2023","journal-title":"J Roy Stat Soc B Stat Methodol"},{"issue":"2","key":"10.1016\/j.ejso.2025.109752_bib11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10120-011-0041-5","article-title":"Japanese classification of gastric carcinoma: 3rd English edition","volume":"14","year":"2011","journal-title":"Gastric Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2025.109752_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-016-0622-4","article-title":"Japanese gastric cancer treatment guidelines 2014 (ver. 4)","volume":"20","year":"2017","journal-title":"Gastric Cancer"},{"issue":"2","key":"10.1016\/j.ejso.2025.109752_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien-Dindo classification of surgical complications: five-year experience","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.ejso.2025.109752_bib14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cac2.12516","article-title":"The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer","volume":"44","author":"Wang","year":"2023","journal-title":"Cancer Commun"},{"issue":"suppl 5","key":"10.1016\/j.ejso.2025.109752_bib15","doi-asserted-by":"crossref","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","article-title":"Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Smyth","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2025.109752_bib16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s10120-024-01558-7","article-title":"Neoadjuvant chemotherapy in relation to long-term mortality in individuals cured of gastric adenocarcinoma","volume":"28","author":"Leijonmarck","year":"2025","journal-title":"Gastric Cancer"},{"issue":"10184","key":"10.1016\/j.ejso.2025.109752_bib17","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.ejso.2025.109752_bib18","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2025.109752_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-024-01536-7","article-title":"Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II\/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial","volume":"17","author":"Wang","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2025.109752_bib20","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/jso.23301","article-title":"Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210)","volume":"107","author":"Iwasaki","year":"2013","journal-title":"J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2025.109752_bib21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/annonc\/mdu472","article-title":"Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer","volume":"26","author":"Yamada","year":"2015","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2025.109752_bib22","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1470-2045(20)30315-6","article-title":"S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial","volume":"21","author":"Kang","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2025.109752_bib23","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/dote.12332","article-title":"Accuracy of staging laparoscopy in detecting peritoneal dissemination in patients with gastroesophageal adenocarcinoma","volume":"29","author":"Simon","year":"2016","journal-title":"Dis Esophagus"},{"issue":"3","key":"10.1016\/j.ejso.2025.109752_bib24","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s10120-018-0884-0","article-title":"A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial","volume":"22","author":"Hosoda","year":"2019","journal-title":"Gastric Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2025.109752_bib25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10120-008-0496-1","article-title":"Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002)","volume":"12","author":"Kinoshita","year":"2009","journal-title":"Gastric Cancer"},{"issue":"117","key":"10.1016\/j.ejso.2025.109752_bib26","first-page":"1638","article-title":"Usefulness of multidisciplinary therapy combining neoadjuvant chemotherapy with S-1 plus cisplatin and postoperative sequential chemotherapy in patients with scirrhous gastric cancer","volume":"59","author":"Oshima","year":"2012","journal-title":"Hepatogastroenterology"},{"issue":"1","key":"10.1016\/j.ejso.2025.109752_bib27","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1186\/s12885-022-09890-w","article-title":"Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study","volume":"22","author":"Endo","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejso.2025.109752_bib28","series-title":"Treatment heterogeneity with right-censored outcomes using grf","author":"Sverdrup","year":"2023"},{"issue":"5","key":"10.1016\/j.ejso.2025.109752_bib29","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/SLA.0000000000006108","article-title":"New onset geriatric syndromes and one-year outcomes following elective gastrointestinal cancer surgery","volume":"279","author":"Melucci","year":"2024","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.ejso.2025.109752_bib30","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s10120-024-01522-5","article-title":"Discontinuation of neoadjuvant therapy does not influence postoperative short-term outcomes in elderly patients (\u2265 70 years) with resectable gastric cancer: a population-based study from the Dutch upper gastrointestinal cancer audit (DUCA) data","volume":"27","author":"Wang","year":"2024","journal-title":"Gastric Cancer"},{"issue":"11","key":"10.1016\/j.ejso.2025.109752_bib31","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1007\/s00432-020-03268-w","article-title":"Gastric cancer in young patients: a separate entity with aggressive features and poor prognosis","volume":"146","author":"Cheng","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2025.109752_bib32","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s10120-023-01404-2","article-title":"Neoadjuvant chemotherapy in older patients with gastric cancer undergoing surgery: a population-based cohort study","volume":"26","author":"Keywani","year":"2023","journal-title":"Gastric Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2025.109752_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2023.101600","article-title":"Efficacy and safety of systemic chemotherapy for radically resectable esophago-gastric adenocarcinoma in older patients: a systematic review and meta-analysis","volume":"15","author":"Noguez-Ramos","year":"2024","journal-title":"J Geriatr Oncol"},{"issue":"19","key":"10.1016\/j.ejso.2025.109752_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/nu15194156","article-title":"Pretreatment modified glasgow prognostic score for predicting prognosis and survival in elderly patients with gastric cancer treated with perioperative FLOT","volume":"15","author":"Melekoglu","year":"2023","journal-title":"Nutrients"},{"issue":"12","key":"10.1016\/j.ejso.2025.109752_bib35","doi-asserted-by":"crossref","first-page":"7040","DOI":"10.1245\/s10434-021-09880-5","article-title":"Association of obesity with worse operative and oncologic outcomes for patients undergoing gastric cancer resection","volume":"28","author":"Nakauchi","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2025.109752_bib36","doi-asserted-by":"crossref","first-page":"9922","DOI":"10.1038\/s41598-021-89385-z","article-title":"Tumor apelin and obesity are associated with reduced neoadjuvant chemotherapy response in a cohort of breast cancer patients","volume":"11","author":"Gourgue","year":"2021","journal-title":"Sci Rep"},{"issue":"25","key":"10.1016\/j.ejso.2025.109752_bib37","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1200\/JCO.2007.14.4527","article-title":"Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer","volume":"26","author":"Litton","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2025.109752_bib38","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1038\/s41416-023-02259-1","article-title":"Impact of obesity on chemotherapy dosing of carboplatin and survival of women with ovarian cancer","volume":"128","author":"Martin","year":"2023","journal-title":"Br J Cancer"},{"issue":"18","key":"10.1016\/j.ejso.2025.109752_bib39","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1200\/JCO.21.00471","article-title":"Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update","volume":"39","author":"Griggs","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl_2","key":"10.1016\/j.ejso.2025.109752_bib40","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/annonc\/mdx810","article-title":"Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy","volume":"29","author":"Baracos","year":"2018","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2025.109752_bib41","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11912-016-0546-5","article-title":"Clinical implications of sarcopenic obesity in cancer","volume":"18","author":"Carneiro","year":"2016","journal-title":"Curr Oncol Rep"},{"issue":"9","key":"10.1016\/j.ejso.2025.109752_bib42","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/jjco\/hyae080","article-title":"Sarcopenic obesity predicts short- and long-term outcomes after neoadjuvant chemotherapy and surgery for gastric cancer","volume":"54","author":"Duan","year":"2024","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2025.109752_bib43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5230\/jgc.2017.17.e8","article-title":"Body composition as a prognostic factor of neoadjuvant chemotherapy toxicity and outcome in patients with locally advanced gastric cancer","volume":"17","author":"Palmela","year":"2017","journal-title":"J Gastric Cancer"},{"issue":"7","key":"10.1016\/j.ejso.2025.109752_bib44","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.ejso.2025.109752_bib45","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.7150\/jca.30371","article-title":"Comparison on clinicopathological features, treatments and prognosis between proximal gastric cancer and distal gastric cancer: a national cancer data base analysis","volume":"10","author":"Wang","year":"2019","journal-title":"J Cancer"},{"issue":"10294","key":"10.1016\/j.ejso.2025.109752_bib46","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"10389","key":"10.1016\/j.ejso.2025.109752_bib47","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ejso.2025.109752_bib48","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325001805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325001805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:38:23Z","timestamp":1762310303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798325001805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0748798325001805"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2025.109752","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying potential beneficiaries of neoadjuvant therapy in borrmann type III and IV gastric cancer: A treatment heterogeneity analysis using causal survival forests","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2025.109752","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109752"}}